Osiris: Osiris Therapeutics shareholders suing to block acquisition by Smith & Nephew - 5 insights
Two Osiris Therapeutics shareholders brought a class-action lawsuit against Osiris in an attempt to block the company's pending $660 million merger with Smith & Nephew.
Read full article »
CEO
Osiris Therapeutics is a Maryland-based biotechnology company that researches, develops and commercializes stem cell therapy for tissue regeneration.
Read more